Drug of choice for acute attack of hereditary angioneurotic edema is
Icatibant (Firazyr), a selective bradykinin B2 receptor antagonist, was approved by the US Food and Drug Administration for treatment of acute attacks HAE in adults. Approval was based on 3 double-blind, randomized, controlled clinical trials known as For Angioedema Subcutaneous Treatment (FAST) Ref Davidson 23rd edition pg 481
Danazol
Cl inhibitor concentrate
Icatibant
Methylprednisolone
Miscellaneous